Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
620
Shown on this page
12
Current sort
Recently updated
Campus scope
Beth Israel Deaconess Medical Center, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Beth Israel Deaconess Medical Center, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 349–360 of 620 matching trials with a site at Beth Israel Deaconess Medical Center, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
Site status not listed — check the official record
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235
Site status not listed — check the official record
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
90
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation, No Radiation
Radiation · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
2,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
451
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
Site status not listed — check the official record
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
Site status not listed — check the official record
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Recruiting Phase 3 Interventional

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

NCT06066502
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
Precision ventilation, Guided usual care ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

NCT05377996
Status at this site: Recruiting
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Interventions
Emi-Le
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT06498960
Site status not listed — check the official record
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
CereVasc eShunt System, VP Shunt
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
60 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910
Site status not listed — check the official record
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
Site status not listed — check the official record
View directory record Official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions
troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

NCT02764541
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
11
States / cities
Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 5:28 PM EDT
Not yet recruiting Phase 2 Interventional

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 5:28 PM EDT

About this Beth Israel Deaconess Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.